Episurf Medical announced the commencement of a prospective investigator-initiated study with 2 years’ follow-up of 25 Episealer® Talus patients. The study is underway at Royal National Orthopaedic Hospital, the largest orthopedic hospital in the U.K.
The study will evaluate the clinical performance of the Episealer Talus implant in patients who undergo surgical treatment with the implant at the hospital. Episealer Talus is Episurf Medical’s CE-marked joint implant intended for treatment of osteochondral ankle lesions.
“We are grateful that the Royal National Orthopaedic Hospital has initiated this study. Clinical evidence is of highest importance for us while we are also focusing on entering new markets. The fact that this reputable hospital decided to perform this study, confirms to us the genuine interest in the U.K. for our technology,” said Pål Ryfors, CEO Episurf Medical.
Episurf Medical announced the commencement of a prospective investigator-initiated study with 2 years’ follow-up of 25 Episealer® Talus patients. The study is underway at Royal National Orthopaedic Hospital, the largest orthopedic hospital in the U.K.
The study will evaluate the clinical performance of the Episealer Talus implant in patients who...
Episurf Medical announced the commencement of a prospective investigator-initiated study with 2 years’ follow-up of 25 Episealer® Talus patients. The study is underway at Royal National Orthopaedic Hospital, the largest orthopedic hospital in the U.K.
The study will evaluate the clinical performance of the Episealer Talus implant in patients who undergo surgical treatment with the implant at the hospital. Episealer Talus is Episurf Medical’s CE-marked joint implant intended for treatment of osteochondral ankle lesions.
“We are grateful that the Royal National Orthopaedic Hospital has initiated this study. Clinical evidence is of highest importance for us while we are also focusing on entering new markets. The fact that this reputable hospital decided to perform this study, confirms to us the genuine interest in the U.K. for our technology,” said Pål Ryfors, CEO Episurf Medical.
Copy to clipboard 
